Literature DB >> 29902520

Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.

Zhining Wen1, Yu Liang1, Yingyi Hao1, Brian Delavan2, Ruili Huang3, Mike Mikailov4, Weida Tong5, Menglong Li6, Zhichao Liu7.   

Abstract

Drug-induced rhabdomyolysis (DIR) is an idiosyncratic and fatal adverse drug reaction (ADR) characterized in severe muscle injuries accompanied by multiple-organ failure. Limited knowledge regarding the pathophysiology of rhabdomyolysis is the main obstacle to developing early biomarkers and prevention strategies. Given the lack of a centralized data resource to curate, organize, and standardize widespread DIR information, here we present a Drug-Induced Rhabdomyolysis Atlas (DIRA) that provides DIR-related information, including: a classification scheme for DIR based on drug labeling information; postmarketing surveillance data of DIR; and DIR drug property information. To elucidate the utility of DIRA, we used precision dosing, concomitant use of DIR drugs, and predictive modeling development to exemplify strategies for idiosyncratic ADR (IADR) management. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29902520      PMCID: PMC7050640          DOI: 10.1016/j.drudis.2018.06.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  30 in total

1.  Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin.

Authors:  A Juhani Kahri; Miia M Valkonen; Matti K E Vuoristo; Pertti J Pentikäinen
Journal:  Ann Pharmacother       Date:  2004-02-13       Impact factor: 3.154

2.  Risk factors for rhabdomyolysis with simvastatin and atorvastatin.

Authors:  Beatrice Golomb; Marcella Evans
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

4.  Risk factors for statin-associated rhabdomyolysis.

Authors:  Stephanie Schech; David Graham; Judy Staffa; Susan E Andrade; Lois La Grenade; Margaret Burgess; David Blough; Andy Stergachis; K Arnold Chan; Richard Platt; Deborah Shatin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

Review 5.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science.

Authors:  Hong Fang; Stephen C Harris; Zhichao Liu; Guangxu Zhou; Guoping Zhang; Joshua Xu; Lilliam Rosario; Paul C Howard; Weida Tong
Journal:  Drug Discov Today       Date:  2016-06-15       Impact factor: 7.851

Review 7.  Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Authors:  Yiannis S Chatzizisis; Konstantinos C Koskinas; Gesthimani Misirli; Christos Vaklavas; Apostolos Hatzitolios; George D Giannoglou
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

8.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

9.  Withdrawal of cerivastatin from the world market.

Authors:  Curt D Furberg; Bertram Pitt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

10.  The SIDER database of drugs and side effects.

Authors:  Michael Kuhn; Ivica Letunic; Lars Juhl Jensen; Peer Bork
Journal:  Nucleic Acids Res       Date:  2015-10-19       Impact factor: 16.971

View more
  2 in total

1.  Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data.

Authors:  Elena Ramírez; Mikel Urroz; Amelia Rodríguez; Miguel González-Muñoz; Alberto Martín-Vega; Yuri Villán; Enrique Seco; Jaime Monserrat; Jesús Frías; Antonio J Carcas; Alberto M Borobia
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

2.  Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis.

Authors:  Betul Borku Uysal; Hande Ikitimur; Serap Yavuzer; Mehmet Sami Islamoglu; Mahir Cengiz
Journal:  Am J Trop Med Hyg       Date:  2020-06-19       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.